What is the main news in this 8-K filing?

The main news is that a jury ruled in favor of Boston Scientific, finding that Johnson & Johnson's CYPHER drug-eluting stent and other J&J stents infringe on Boston Scientific's patents related to stent design and polymer coatings. The jury also upheld the validity of these patents.

What are the implications of this jury verdict for Boston Scientific?

This verdict is a significant legal and potential financial win for Boston Scientific. It strengthens their position in the cardiovascular device market, validates their intellectual property, and opens the door for potential damages awarded in a future hearing.

What happens next regarding damages?

The filing states that a hearing will be held at a later date to determine the amount of damages and any other relief that will be awarded to Boston Scientific as a result of the infringement.

Which specific Johnson & Johnson products are involved in this lawsuit?

The jury's verdict specifically addresses Johnson & Johnson's CYPHER drug-eluting stent for infringing the polymer coating patent, and the CYPHER, Bx VELOCITY, Bx SONIC, and GENESIS stents for infringing the stent design patent.

BSX 8-K SEC Disclosure

Summary

Boston Scientific Corporation (BSX) announced a significant legal victory on July 1, 2005. A jury in the United States District Court in Delaware found that Johnson & Johnson's CYPHER drug-eluting stent infringes on two of Boston Scientific's patents. Specifically, one patent covers polymer coatings, and the other relates to stent design. The jury also affirmed the validity of both of Boston Scientific's patents, which is a crucial aspect of the ruling.

Key Highlights

1Jury found Johnson & Johnson's CYPHER drug-eluting stent infringes Boston Scientific's patent on polymer coatings.
2Jury found Johnson & Johnson's CYPHER, Bx VELOCITY, Bx SONIC, and GENESIS stents infringe Boston Scientific's patent on stent design.
3The validity of both Boston Scientific's patents was upheld by the jury.
4This ruling represents a favorable outcome for Boston Scientific in a key intellectual property dispute within the cardiovascular device market.
5A subsequent hearing will be scheduled to determine damages and any other relief awarded to Boston Scientific.
6The event date for this report is June 30, 2005, with the filing occurring on July 6, 2005.

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Jul 7, 2005)

Summary

Key Highlights

Frequently Asked Questions